Genmab A-S Aktie

181,95 EUR +2,25 EUR +1,25 %

21:49:55

FSE

183,75 EUR -2,75 EUR -1,47 %

17:50:05

GVIE

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.11,78 Mrd. EUR

KGV12,21Div. Rendite0,00%

WKN565131

ISINDK0010272202

SymbolGNMSF

Genmab A-S Aktien News

Sortieren:Datum Meistgelesen

21.07.23GlobeNewswireGenmab Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)

20.07.23GlobeNewswireGenmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2023

19.07.23finanzen.netErste Schätzungen: Genmab A-S stellt das Zahlenwerk zum vergangenen Quartal vor

19.07.23finanzen.netErste Schätzungen: Genmab A-S (spons ADRs) mit Zahlen zum abgelaufenen Quartal

28.06.23GlobeNewswireGenmab and AbbVie Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody® CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

22.06.23GlobeNewswireGenmab Announces Epcoritamab Added to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for ‘B-Cell Lymphomas’

20.06.23GlobeNewswireCapital Increase in Genmab as a Result of Employee Warrant Exercise

09.06.23GlobeNewswireGenmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas at European Hematology Association (EHA) Annual Meeting 2023

08.06.23GlobeNewswireGrant of Restricted Stock Units and Warrants to Employees in Genmab

06.06.23GlobeNewswireGenmab to Participate in a Fireside Chat at the Goldman Sachs 44th Annual Global Healthcare Conference

01.06.23GlobeNewswireTransactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

31.05.23GlobeNewswireTransactions with Shares and Linked Securities in Genmab A/S Made By Managerial Employees and Their Closely Associated Persons

25.05.23GlobeNewswireGenmab Announces Multiple Abstracts to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Congress

23.05.23GlobeNewswireCapital Increase in Genmab as a Result of Employee Warrant Exercise

19.05.23GlobeNewswireEPKINLY™ (epcoritamab-bysp) Approved by U.S. Food and Drug Administration as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLB

11.05.23finanzen.netGenmab A-S: Das sind die jüngsten Quartalszahlen

11.05.23finanzen.netGenmab A-S (spons ADRs) stellte Zahlen zum jüngsten Quartal vor

10.05.23GlobeNewswireGenmab Announces Financial Results for the First Quarter of 2023

09.05.23finanzen.netAusblick: Genmab A-S stellt das Zahlenwerk zum vergangenen Quartal vor

09.05.23finanzen.netAusblick: Genmab A-S (spons ADRs) präsentiert Bilanzzahlen zum jüngsten Jahresviertel

25.04.23finanzen.netErste Schätzungen: Genmab A-S präsentiert das Zahlenwerk zum abgelaufenen Jahresviertel

25.04.23finanzen.netErste Schätzungen: Genmab A-S (spons ADRs) zieht Bilanz zum abgelaufenen Quartal

24.04.23GlobeNewswireGenmab To File Appeal in Its Second Arbitration Under License Agreement with Janssen

21.04.23GlobeNewswireGenmab Announces Initial Resolution of Its Second Arbitration Under License Agreement with Janssen

18.04.23GlobeNewswireGenmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2023

17.04.23GlobeNewswireGenmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology

06.04.23GlobeNewswireTransactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

03.04.23GlobeNewswireTransactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

03.04.23GlobeNewswireCompletion of share buy-back program

29.03.23GlobeNewswireTransactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

29.03.23GlobeNewswireConstitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab

29.03.23GlobeNewswirePassing of Genmab A/S’ Annual General Meeting

28.03.23GlobeNewswireGenmab Announces Appointment of Martine van Vugt to Chief Strategy Officer

27.03.23GlobeNewswireTransactions in connection with share buy-back program

20.03.23GlobeNewswireTransactions in connection with share buy-back program

13.03.23GlobeNewswireTransactions in connection with share buy-back program

06.03.23GlobeNewswireTransactions in connection with share buy-back program

28.02.23GlobeNewswireCapital Increase in Genmab as a Result of Employee Warrant Exercise

27.02.23GlobeNewswireTransactions in connection with share buy-back program

Genmab A-S News

Genmab A-S News: auf dieser Seite finden Sie alle Genmab A-S News und Nachrichten zur Genmab A-S Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Genmab A-S News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Genmab A-S News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.